Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-23

Clinical Trial Update: Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the effectiveness of semaglutide in individuals who are overweight or obese has completed, with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2022-03-23